PRAMIPEXOLE DIHYDROCHLORIDE (pramipexole dihydrochloride) by PharmaIN is non-ergot dopamine agonist with high relative in vitro specificity and full intrinsic activity at the d 2 subfamily of dopamine receptors, binding with higher affinity to d 3 than to d 2 or d 4 receptor subtypes. Approved for parkinson's disease (pd) () pramipexole dihydrochloride extended- release tablets are indicated for the treatment of parkinson's disease. First approved in 2022.
Drug data last refreshed 18h ago
non-ergot dopamine agonist with high relative in vitro specificity and full intrinsic activity at the D 2 subfamily of dopamine receptors, binding with higher affinity to D 3 than to D 2 or D 4 receptor subtypes. The precise mechanism of action of pramipexole as a treatment for Parkinson's disease…
Worked on PRAMIPEXOLE DIHYDROCHLORIDE at PharmaIN? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Bipolar Study of Seroquel XR With Pramipexole Dihydrochloride
Pramipexole Dihydrochloride 0.25 mg Tablets Under Fasting Conditions
Pramipexole Dihydrochloride 0.25 mg Tablets Under Non-Fasting Conditions